Washed microbiota transplantation alleviates tyrosine kinase inhibitors associated gastrointestinal adverse effects

Weihong Wang1,2, Xinyi He1,2, Chenchen Liang1,2

  • 1Department of Microbiota Medicine & Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Insights

Washed microbiota transplantation (WMT) effectively treats tyrosine kinase inhibitor-induced gastrointestinal issues in cancer patients. This gut health therapy shows promise for managing side effects when standard treatments fall short.

Area of Science:

  • Gastroenterology
  • Oncology
  • Microbiology

Background:

  • Gut microbiota dysbiosis is linked to tyrosine kinase inhibitor (TKI)-induced gastrointestinal adverse effects (GAEs).
  • GAEs can lead to dose adjustments or treatment cessation, impacting cancer therapy efficacy.
  • Current management strategies for TKI-induced GAEs may be insufficient for some patients.

Purpose of the Study:

  • To assess the efficacy and safety of washed microbiota transplantation (WMT) for managing TKI-induced GAEs.
  • To determine clinical remission and asymptomatic rates following WMT.
  • To evaluate changes in C-reactive protein (CRP) levels as a marker of inflammation.

Main Methods:

  • A prospective study involving cancer patients experiencing TKI-induced GAEs.
  • Patients received washed microbiota transplantation (WMT).
  • Outcomes measured included clinical remission, asymptomatic status, time to remission, and CRP levels using standard grading criteria.

Main Results:

  • A 75% clinical remission rate was observed at 8 weeks post-WMT.
  • Significant improvements were noted in diarrhea, abdominal pain, and distention (p < .05).
  • C-reactive protein levels decreased significantly, and no severe adverse events were reported.

Conclusions:

  • Washed microbiota transplantation (WMT) is a safe and effective option for TKI-induced GAEs.
  • WMT offers a potential therapeutic avenue for patients unresponsive to conventional treatments.
  • Further research may explore WMT's role in maintaining long-term remission and preventing GAE relapse.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...